Breaking News

Hummingbird, Endeavor Partner on Next-Gen HER3-Targeted ADC

Endeavor obtains exclusive rights to Hummingbird Bioscience’s anti-HER3 ADC to be developed for patients with HER3-expressing tumors.

Hummingbird Bioscience Pte Ltd., a data-driven precision biotherapeutics company, and Endeavor BioMedicines, a clinical-stage company targeting the drivers of fibrosis and oncology, reported that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501. The license agreement provides Endeavor with exclusive rights to HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for safety and efficacy. Hummi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters